Elacytarabine

Drug Profile

Elacytarabine

Alternative Names: CP-4055; ELACYT; UNII-TA7WJG93AR

Latest Information Update: 12 Nov 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Clavis Pharma
  • Developer Aqualis; Clavis Pharma
  • Class Antineoplastics; Arabinonucleosides; Oleic acids; Pyrimidine nucleosides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Colorectal cancer; Malignant melanoma; Ovarian cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 29 Aug 2013 Discontinued - Phase-II for Acute myeloid leukaemia (combination therapy, early-stage disease, second-line or greater) in France, Germany, Norway and USA (IV)
  • 29 Aug 2013 Discontinued - Phase-III for Acute myeloid leukaemia (late-stage disease) in Australia, Belgium, Canada, France, Germany, Ireland, Italy, Norway, Poland, Romania, Spain, United Kingdom and USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top